Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial.

Wolfgang P. Fendler,J Ferdinandus,Jeremie Calais,Matthias Eiber,Robert R. Flavell,Ashley Mishoe,Felix Y. Feng,Hao Gia Nguyen,Robert E. Reiter,Matthew Rettig,Jeannine Gartmann,Raven Smith,Eric J. Small,Roger Slavik,Peter R. Carroll,Ken Herrmann,Johannes Czernin,Thomas A. Hope

Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial.

2020

Wolfgang P. Fendler
J Ferdinandus
Jeremie Calais
Matthias Eiber
Robert R. Flavell
Ashley Mishoe
Felix Y. Feng
Hao Gia Nguyen
Robert E. Reiter
Matthew Rettig
Jeannine Gartmann
Raven Smith
Eric J. Small
Roger Slavik
Peter R. Carroll
Ken Herrmann
Johannes Czernin
Thomas A. Hope

292Background: Prostate-specific membrane antigen ligand positron emission tomography (PSMA PET) induced management changes in up to every second patient in smaller clinical trials. We aim to deter...

Keywords:

Oncology
Clinical trial
Pathology
Internal medicine
Recurrent prostate cancer
68Ga-PSMA-11
Medicine
membrane antigen
psma pet
Positron emission tomography

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations